Persistence of even the stealthiest viruses can perturb immune function either to the benefit or detriment of the host. Lymphocytic choriomeningitis virus (LCMV) establishes lifelong, systemic persistence when introduced in utero or at birth. Despite a highly evolved host-pathogen relationship, LCMV cannot escape detection by the innate immune system, which results in chronic stimulation of the type 1 IFN pathway in adult carrier mice. In this study we demonstrate that IFN-β is chronically up-regulated in peripheral lymphoid and nonlymphoid tissues (but not the CNS) of mice persistently infected from birth with LCMV and that dendritic cells (DCs) represent at least one source of IFN-β. Interestingly, chronic stimulation of this innate pathway significantly elevated MHC class I expression in the CNS as well as the periphery. Elevated MHC I expression was dependent on IFN-αβ receptor but not MyD88-dependent signaling, as only genetic deletion of the former reduced MHC I to normal levels. An increase in circulating virus was also observed in the IFN-αβ receptor deficient carrier mice, signifying that type I IFN continually exerts anti-viral pressure during a LCMV carrier state. Finally, to determine whether heightened CNS MHC I could be therapeutically corrected, we purged LCMV carrier mice of their persistent infection using adoptive immunotherapy. This treatment significantly reduced CNS MHC I expression. Collectively, these data demonstrate that even a well adapted pathogen can chronically stimulate the innate immune system and consequently alter the expression of Ag presenting machinery in an immunologically specialized compartment like the CNS.
(e.g., growth hormone production) (6) , cognitive dysfunction (7) , and systemic autoimmune disease (8) in mice infected with lymphocytic choriomeningitis virus (LCMV). 3 These select few examples represent only a small fraction of the total burden persistent viruses impose on biological systems. However, at the opposite end of the spectrum, viruses that persist can also benefit the host. For example, it was shown recently that mice persistently infected with gamma herpesvirus 68 or cytomegalovirus have enhanced resistance to Listeria monocytogenes and Yersinia pestis (9) . In addition, mice persistently infected with LCMV were shown to have elevated surveillance and clearance of tumor cells (10) . Thus, there are in some cases advantages to having a persistent viral infection.
LCMV is a member of the arenavirus family and can differentially impact the CNS compartment depending on when the virus is introduced (11) . Intracerebral inoculation of adult immunocompetent mice with LCMV Armstrong (Arm) results in acute fatal meningitis within 6-7 days, whereas an asymptomatic carrier state develops when the same virus is introduced in utero or 1 day following birth. The asymptomatic carrier state is of significant interest from an immunological perspective, because carriers are tolerant to LCMV at the T cell level (12) , which enables the virus to establish lifelong persistence in its natural host. During the carrier state, the virus localizes systemically, residing in nearly every tissue (13) , and within the CNS parenchyma, the virus is found almost exclusively in neurons (14, 15) . Neurons are thought to represent a safe house for the virus, because of their minimal expression of MHC class I (MHC I) (16, 17) . Nevertheless, neurons as well as systemically distributed LCMV can be purged from carrier mice by infusing them with virus-specific memory cells obtained from previously immunized mice (18, 19) . Over the years LCMV carrier mice have provided a useful model for refining our understanding of adoptive immunotherapy, an approach that has been successfully translated to controlling persistent human viral infections (20) .
In most strains of mice, the LCMV carrier state represents a well-balanced equilibrium between host and pathogen. The adaptive immune system is in part tolerant to LCMV in carrier mice, but, presently, little is known about how this persistent infection perturbs innate function, particularly within the CNS which normally maintains low basal immunological activity (21) . A high potential for innate immune stimulation exists in carrier mice, as all conventional dendritic cell (DC) subsets harbor LCMV Ag (22) . In fact, two previous studies documented low, but detectable levels of type 1 IFN in the sera of LCMV carrier mice (10, 23) .
Moreover, when the "molecular signature" of LCMV persistence was examined by gene array in the CNS of carrier mice, the majority of the up-regulated genes were IFN-stimulated genes (24) . These data suggest that even after equilibrating with its murine host, LCMV continues to trip innate sensors during a carrier state, giving rise to low level, chronic stimulation of the immune system.
Based on the aforementioned studies, it seemed improbable that LCMV could avoid chronic innate immune stimulation in carrier mice. We therefore set out to address the biological impact of chronic innate stimulation by LCMV, focusing almost exclusively on the CNS because of its normally quiescent immune status. Because innate immune stimulation is linked to Ag presentation, we first addressed whether classical Ag presenting machinery (i.e., MHC I) was elevated in the CNS of carrier mice. Having established that MHC I was indeed up-regulated in carrier mice, we next sought the source of the MHC I and the mechanism by which it was up-regulated. Lastly, we evaluated whether chronic elevation of CNS MHC I was dependent on persisting virus by therapeutically purging LCMV from adult carrier mice. Our collective studies shed light on the degree and mechanism by which LCMV perturbs innate immune function during a state of lifelong persistence.
Materials and Methods
Mice C57BL/6 (B6), B6 IFN-αβ R −/− , B6 MyD88 −/− , and B6 CD11c-DTR were bred and maintained in a closed breeding facility at The Scripps Research Institute. The handling of all mice conformed to the requirements of the National Institutes of Health and The Scripps Research Institute animal research committee.
Virus
To establish a B6 LCMV carrier colony, newborn mice (1 day old) were infected intracerebrally with 1 × 10 3 PFU of LCMV Arm clone 53b. The resultant carrier mice were then interbred to establish new carrier mice through vertical transmission (i.e., passage of virus from mother to offspring). Carrier colonies of IFN-αβ R −/− and MyD88 −/− were generated by first crossing an uninfected male of the respective knockout strains with a female B6 carrier mouse. The resultant persistently LCMV infected F1 mice were then intercrossed to obtain +/+, +/−, and −/− mice in the F 2 generation. CD11c-DTR carrier mice and transgene negative littermate controls were generated by crossing an uninfected +/− male with a B6 carrier female. Stocks of LCMV Arm were prepared by a single passage on BHK-21 cells, and viral titers were determined by plaque formation on Vero cells. The phenotypic and genotypic characterization of LCMV Arm, and viral plaque assays for quantification are described elsewhere (25) .
Mononuclear cell isolations and tissue processing
To obtain cell suspensions for flow cytometric analysis, the brain and spinal cord were harvested from mice after an intracardiac perfusion with a 0.9% saline solution to remove the contaminating blood lymphocytes. The CNS organs were then incubated with 1 ml of collagenase D (1 mg/ml; Roche) at 37°C for 20 min. Single-cell suspensions were then prepared by mechanical disruption through a 100-µm filter. To extract brain-infiltrating leukocytes, homogenates were resuspended in 90% Percoll (4 ml), which was overlaid with 60% Percoll (3 ml), 40% Percoll (4 ml), and 1× HBSS (3 ml). The Percoll gradients were then centrifuged at 1,500 RPM for 15 min, after which the band corresponding to mononuclear cells was carefully extracted, washed, and analyzed. For immunohistochemical analyses, fresh, unfixed tissues were frozen on dry ice in optimal cutting temperature (Tissue-Tek). For the detection of infectious virus in the CNS, brains were cut sagittally and then half was homogenized using a Mini Beadbeater (BioSpec Products). Homogenates were analyzed using a standard plaque assay on Vero cells. Viral titers in the blood were determined by performing plaque assays on sera.
Adoptive immunotherapy
To generate memory donor mice for immunocytotherapy, B6 mice were infected i.p. with 1 × 10 5 PFU of LCMV Arm, which is consistently cleared in 8-10 days. At day 45 postinfection, splenocytes were harvested from the resultant memory mice and 2 × 10 7 of these cells were injected i.p. into LCMV carrier mice (14) .
Flow cytometry
CNS mononuclear cells were harvested and blocked with 3.3 µg/ml anti-mouse CD16/CD32 (Fc Block; BD Biosciences) in PBS containing 1% FBS and 0.5% sodium azide for 10 min on ice. After Fc block, the cells were stained with mixtures of the following Abs purchased from BD Biosciences: anti-CD45.2-FITC, anti-D b -PE, anti-IgG-PE (isotype control), anti-Thy1.2-PE, anti-CD11b-PECy7, anti-CD4-PerCP, anti-CD11b-allophycocyanin, and anti-CD11c-allophycocyanin. Anti-CD8-Pacific Blue was purchased from Caltag Laboratories. Cells were acquired using a digital flow cytometer (Digital LSR II; BD Biosciences) and flow cytometric data were analyzed with FlowJo software (Tree Star).
Immunohistochemistry
To visualize MHC I (Figs. 1, 4, and 7, and supplementary Fig. S1 ), 4 6-µm frozen sections were cut, fixed with cold ethanol for 10 min, blocked with an avidin/biotin-blocking kit (Vector Laboratories), and stained for 1 h at room temperature with rat anti-mouse MHC class I (clone ER-HR 52; 1/100; Abcam). After the primary Ab incubation, sections were washed, stained for 1 h at room temperature with a biotinylated secondary Ab (1/400; Jackson ImmunoResearch Laboratories), washed, and stained for 1 h at room temperature with streptavidin-Rhodamine Red-X (1/400; Jackson ImmunoResearch Laboratories). For colabeling studies ( Fig. 2 and supplemental Figs. S2 and S3) primary Abs directed against endothelium (anti-CD31; 1/200; Chemicon), astrocytes (anti-GFAP; 1/800, Dako-Cytomation), or neurons (anti-NeuN; 1/800; Chemicon) were added to the aforementioned MHC I staining protocol. The cell marker-specific Abs were detected with secondaries conjugated to FITC (1/400; Jackson ImmunoResearch Laboratories). Because anti-NeuN is a mouse primary, an additional blocking step was added to all stains involving this Ab. Specifically, endogenous mouse Abs were blocked by preincubating sections for 1 h at room temperature with 35 µg/ml a Fab anti-mouse H and L chain Ab (Jackson ImmunoResearch Laboratories). After all immunohistocheical procedures, sections were costained for 5 min at room temperature with 1 µg/ml 4′,6-diamidino-2-phenylindole (Sigma-Aldrich) to visualize cell nuclei. All working stocks of primary and secondary reagents were diluted in PBS containing 2% FBS.
Microscopy
Two-color organ reconstructions (Figs. 1, 4, and 7, and supplementary Fig. S1 ) to visualize the distribution of MHC I on 6-µm frozen sections were obtained using an immunofluorescence microscope (Axiovert S100; Carl Zeiss MicroImaging) fitted with an automated xy stage, a color digital camera (Axiocam; Carl Zeiss MicroImaging), and a ×5 objective. Registered images were captured for each field on the tissue section, and reconstructions were performed using the MosaiX function in KS300 image analysis software (Carl Zeiss MicroImaging). Higher resolution images to examine MHC I expression on endothelium, astrocytes, oligodendrocytes, and neurons ( Fig. 2 and supplemental Figs. S2 and S3) were captured with a MRC1024 confocal microscope (Bio-Rad Laboratories) fitted with a krypton/argon mixed gas laser (excitation at 488, 568, and 647 nm) and a ×40 oil objective (Carl Zeiss MicroImaging).
Image analysis
The level of MHC I expressed on CD31 + vascular endothelium (see Fig. 2 , G-I) was quantified on confocal images using Adobe Photoshop CS (Adobe Systems Incorporated). Five random ×40 two-color fields were captured from each mouse sagittal section (equivalent to 2510 µm 2 of CNS tissue sampled per mouse). Cells corresponding to vascular endothelium (CD31 + ) were outlined manually using the polygon lasso tool. The mean intensity of MHC I staining on each CD31 + cell was then determined using the histogram function. A total of 40 endothelial cells were quantified for each mouse, and the MHC I intensity values were then averaged.
RNA isolation
For RNA isolation, spleen, lymph node, liver, and brain were extracted, placed inside a cryotube, and immediately frozen using liquid nitrogen. Tissues were homogenized using a Mini Beadbeater (BioSpec Products). RNA was then isolated using TRI Reagent (Molecular Research Center) and resuspended in sterile distilled water containing 0.1% diethyl pyrocarbonate (Sigma-Aldrich). To eliminate contaminating DNA, the RNA was incubated with 6 µl of RQ1 RNase free DNase (Promega) per 30 µg of RNA at 37°C for 30 min. Afterward, a 1:1 ratio of DNase:DNase Stop Solution (Promega) was added to each sample and incubated at 65°C for 10 min. All RNA was subsequently stored at −80°C until use.
RT-PCR
IFN-β mRNA was detected using a nested RT-PCR. RNA (1 µg) was reverse transcribed using a reverse primer specific for IFN-β (5′-GTC TCA TTC CAC CCA GTG CT-3′) and m-MLV reverse transcriptase (Promega). The reverse primer was incubated with RNA at 70°C for 5 min and then the reverse transcription reaction was performed at 42°C for 60 min, 95°C for 5 min. Afterward, a PCR was performed on the resultant cDNA using TaqDNA polymerase (5′) and primers specific to the IFN-β receptor (forward primer = 5′-which resulted in a 100-bp product. The forward primer for the nested PCR was 5′-GAT GAC GGA GAA GAT GCA GA-3′, and the reverse primer was 5′-CCC AGT GCT GGA GAA ATT GT-3′. The same PCR conditions described above were used. As a control to ensure equal loading of cDNA, a β-actin RT-PCR was also performed on all isolated RNA samples using identical reagents and PCR cycling conditions. The forward primer for this PCR was 5′-TCA TGA AGT GTG ACG TTG ACA TCC GT-3′ and the reverse primer was 5′-CTT AGA AGC ATT TGC GGT GCA CGA TG-3′. This RT-PCR resulted in a 300-bp DNA fragment. All RT-PCR products were examined by gel electrophoresis.
Quantitative assessment of IFN-β transcripts in the brain
Tissues were homogenized in TRI reagent (Molecular Research Center), and RNA were extracted following manufacturers instructions. RNA samples (1 µg) were treated with DNase I (Invitrogen Life Technologies) and transcribed into cDNA using random primers and Moloney murine leukemia virus reverse transcriptase (Invitrogen Life Technologies). Reactions were performed in 25 µl using the Platinum SYBR Green SuperMix (Invitrogen Life technologies) and analyzed with 7900HT Fast Real-Time PCR system (Applied Biosystems). Cycling conditions were 5 min at 90°C followed by 40 two-temperature cycles (15 s at 90°C and 1 min at 60°C). Data were analyzed with the sequence detection software supplied with the instrument (Applied Biosystems). Transcripts were normalized to hypoxanthine phosphoribosiltransferase (HPRT) transcripts analyzed in parallel. In brief, each set of sample were normalized using ΔC T = (ΔC Tsample -ΔC TsHPRT ). The calibration sample (ΔC Tcalibration ) was assigned as the sample with the lowest ΔC T . Relative mRNA levels were calculated by the expression of 2 −ΔCT , where ΔΔC T = ΔC Tsample -ΔC Tcalibration . Each reaction was performed in duplicate.
CD11c + DC purification
Naive B6 and LCMV carrier spleens (n = 3 per group) were extracted and splenocytes were isolated. Single cell suspensions were prepared by mechanical disruption through a 100-µm filter. Afterward, splenocytes were pooled for each group, treated with RBC lysis buffer (0.14 M NH 4 Cl and 0.017 M Tris-HCl (pH 7.2)), washed twice, and resuspended in precooled PBS containing 2% FBS (FBS). CD11c + DC cells were isolated using Easy Sep mouse CD11c positive selection kit (Stem Cell Technologies). Approximately 4 × 10 6 cells isolated from each group were CD11c positive. RNA was isolated from these cells using the Tri Reagent (Molecular Research Center) and a nested RT-PCR for IFN-β was performed as described above.
Bone marrow chimeras and DC depletion
Femurs were obtained from wild-type B6 or CD11c-DTR carrier mice, and bone marrow was flushed out with RPMI 1640 medium using a 27-gauge syringe. Bone marrow was treated with RBC lysis buffer, washed twice, and resuspended in PBS. Bone marrow chimeras were created by irradiating mice with 1100 rad. The recipients were reconstituted with 2 × 10 7 bone marrow cells and kept on antibiotic drinking water for 3 wk. Four weeks following reconstitution, the chimeras were injected with 2 ng/g DT every third day for 3 wk to deplete DCs. 
Results

MHC I is elevated in the CNS of LCMV carrier mice
In mice persistently infected from birth with LCMV, the virus localizes to neurons, meninges, ependyma, and choroid plexus within the CNS (13, 15) . Despite this widespread distribution, our previous genomic studies demonstrated that a relatively small number of gene transcripts are differentially regulated in the brains of carrier mice when compared naive B6 controls. Interestingly, MHC I mRNA, a gene product that is minimally expressed and strictly regulated in the CNS (16, 17) , was found to be elevated in persistently infected carrier mice. To validate the genomic data at the protein level, we first stained sagittal brain sections from LCMV carrier and naive control mice with an Ab specific to MHC I (Fig. 1, A and B) and then generated tissue reconstructions to permit examination of the entire cross section. A marked increase in the expression of MHC I was noted in the brains of LCMV carrier mice when compared with the uninfected controls. This was confirmed by quantitative image analysis, which revealed a statistically significant (p < 0.042) 4.1-fold increase in the expression of MHC I (Fig. 1C ). The elevated MHC I did not, however, appear to be restricted to any distinct brain regions. The distribution observed on the sagittal brain reconstructions suggested a homogenous MHC I increase throughout the brain parenchyma and meninges. Interestingly, we also observed increased MHC I expression in the periphery of LCMV carrier mice ( Fig. S1 ). For example, liver sections from carrier mice showed a statistically significant (p < 0.003) 59.3-fold increase in MHC I expression when compared with naive controls (Fig. S1 ). Collectively, these data indicate that MHC I, the restricting element for CTL (26) and a molecule important for CNS function (27), is chronically upregulated in the brains and periphery of carrier mice.
MHC I localizes primarily to vascular endothelium in LCMV carrier mice
The homogenous increase in MHC I observed on sagittal brain reconstructions from carrier mice suggested that the MHC I would localize to a common and widely distributed cellular element of the brain parenchyma. An obvious candidate to examine first was neurons, the only population in the brain parenchyma of carrier mice known to harbor LCMV Ag (14, 15) . However, in support of studies demonstrating that neurons express little to no MHC I (16, 17) , we were unable to find MHC I expression on NeuN + neurons in carrier mice ( however, their processes, which extend to myelinate neighboring axons, were mostly MHC I negative. The cell population found to account for nearly all of the MHC I observed in any given field was the vascular endothelium ( Fig. 2) . Low (Fig. 2 , A-C) and high (Fig. 2, D-F) magnification confocal studies revealed that every endothelial cell surrounding the CNS vasculature expressed high levels of MHC I. Using quantitative image analysis, we noted a significant (p = 0.010) 3.0-fold increase in the expression of MHC I on the CNS endothelium of LCMV carrier mice when compared with uninfected controls (Fig. 2 , G-I).
This is of some importance because expression of MHC I on CNS vascular endothelium was recently proposed to serve as a gateway facilitating CTL access into the CNS (28) .
Because astrocytic foot processes comprise the second layer of the blood brain barrier, we theorized that this cell population might also express MHC I in LCMV carrier mice. When colabeling studies were performed, the patterns of MHC I and GFAP + astrocyte staining in carrier mice were found to be largely distinct (Fig. S3 ). Some overlap (yellow) was observed on astrocytic foot processes surrounding parenchymal blood vessels (Fig. S3) ; however, this overlap could be explained by their close proximity to the MHC I + endothelium. Higher spatial resolution would be required to definitively demonstrate that an astrocytic foot process can express MHC I independent from its soma and extending branches, as the latter two astrocytic components were both negative for MHC I expression.
Lastly, we quantified MHC I expression on CNS resident microglia by flow cytometry (Fig.  S4 ). We used flow cytometry rather than microscopy because microglia can be easily isolated from the CNS, and the markers used to distinguish microglia (CD45 low/int CD11b + ) from peripherally derived macrophages (CD45 high CD11b + ) are well defined (29, 30) . When microglia from carrier mice were analyzed for MHC I (D b molecule) expression, a statistically significant (p < 0.001) 3.1-fold increase was noted. Thus, our collective results demonstrate that endothelium and microglia likely account for most (if not all) of the elevated MHC I observed on sagittal brain sections from LCMV carrier mice (Fig. 1B) .
IFN-β mRNA is elevated in the peripheral tissues of LCMV carrier mice
Genomic studies performed on RNA extracted from LCMV carrier brains indicated that several genes downstream from type 1 IFN signaling (IFN-αβ) were elevated in expression (24) . However, no increase in type 1 IFNs were found in the gene array profile, suggesting that they were being produced in the periphery of LCMV carrier mice. Because IFN-αβ are potent inducers of MHC I (31) and are known to be produced during a persistent LCMV infection (10, 23), we next examined whether IFN-β expression (a representative family member) was elevated in brains or peripheral tissues of LCMV carrier mice. Using a RT-PCR approach, elevated IFN-β expression was noted in the spleen, lymph nodes, and liver of carrier mice, but not the CNS (Fig. 3 ). To confirm that IFN-β was not expressed in the CNS of carrier mice, we performed a quantitative RT-PCR. Following normalization to a housekeeping gene, no statistically significant difference (p > 0.05) in IFN-β expression was detected in the CNS of naive (1.49 ± 0.43) vs carrier (1.53 ± 0.92) mice. These data suggest that the chronically elevated type I IFN production observed in carrier mice is likely produced by a cell population abundant in the periphery but not the CNS.
Deficiency in the IFN-αβ receptor reduces CNS MHC I in LCMV carrier mice to a basal level
To determine whether the chronic production of type 1 IFN(s) was responsible for the elevated CNS MHC I expression observed in carrier mice, we crossed B6 IFN-αβ R −/− mice with our wild-type LCMV carrier colony. In the F 2 generation we obtained littermate IFN- 
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Author Manuscript αβ R +/+ and −/− carrier mice. When the expression of MHC I on sagittal brain sections from naive B6 and IFN-αβ R+/+ carrier mice was quantified, a statistically significant (p < 0.05) 10.1-fold increase was observed in the wild-type (IFN-αβ R +/+ ) carrier mice ( Fig. 4 , A, B, and D). These data confirmed our original studies shown in Fig. 1 . Interestingly, deficiency in the IFN-αβ R reduced the expression of CNS MHC I to the levels observed in uninfected B6 mice (Fig. 4, A-D) . The absence of type IIFN signaling also had an impact on the viral set point in LCMV carrier mice. The quantity of LCMV in circulation increased 5.1-fold in IFN-αβ R −/− carrier mice compared with wild-type litter-mate controls. Collectively, these data indicate that type I IFN is responsible for the increased CNS MHC I observed in carrier mice and that this innate cytokine also helps to maintain the welldescribed viral set point observed in carrier mice (32) .
Elevated CNS MHC I in carrier mice does not require MyD88-dependent signaling
Production of type I IFNs following pathogen infection is often associated with upstream engagement of innate sensors (33) . One family of innate sensors first discovered in Drosophila relies on the use of Toll-like receptors. MyD88 is an adaptor protein required for the proper functioning of nearly all Toll-like receptors, and deficiency in MyD88 is frequently used to implicate a TLR family member as an upstream mediator of the type I IFN observed following infection. LCMV infection is thought to engage both Tolldependent and independent pathways of type I IFN production (34) . We therefore set out to determine whether the type I IFN dependent up-regulation of CNS MHC I observed in LCMV carrier mice required MyD88 signaling. This was accomplished by generating a colony of MyD88 −/− LCMV carrier mice. Upon intercrossing MyD88 +/− carrier mice, we first noted a statistically significant (p = 0.008) reduction in the expected Mendelian frequency of MyD88 −/− carrier mice (but not MyD88 +/+ or MyD88 +/− ) in the F 2 generation (Fig. 5A) . These data suggested that intact TLR signaling was important in fostering the survival of mice developing in utero with a persistent LCMV infection. However, in the MyD88 −/− carrier mice that did survive to adulthood, no significant change in viral titers (Fig. 5B ) or CNS MHC I was observed (Fig. 5C ). These data indicate that MyD88dependent signaling was not responsible for the viral set point or the elevated MHC I observed in LCMV carrier mice.
IFN-β mRNA is increased in DCs extracted from LCMV carrier mice
Because elevated IFN-β mRNA was observed in all peripheral tissues sampled, but not the CNS (Fig. 3) , we next sought a cellular source of the type I IFNs that is common to all peripheral tissues, but is not abundant in the CNS. We considered DCs because all conventional DC subsets are known to contain LCMV Ag in carrier mice (22) , and DCs are abundant in the parenchyma of peripheral tissues (both lymphoid and nonlymphoid), but not the CNS. To determine whether DCs from LCMV carrier mice could serve as a source of type I IFN, we purified splenic CD11c + DCs from LCMV carrier mice and compared the expression of IFN-β mRNA in these cells to that observed in DCs from naive mice (Fig.  6A) . As a positive control for this experiment, we purified DCs from the spleens of B6 mice infected 2 days earlier with 2 × 10 6 LCMV clone 13 i.v. The clone 13 variant of LCMV is known to be a potent inducer of type I IFN production in conventional DCs (35) . Interestingly, a marked increase in IFN-β mRNA was observed in splenic DCs extracted from carrier mice. These data indicate that DCs are likely one potential source of type I IFN in carrier mice.
To determine whether peripheral DCs contributed to the observed elevation in CNS MHC I, we generated bone marrow chimeras of adult B6 LCMV carrier mice reconstituted with CD11c-diphtheria toxin (DT) receptor (CD11c-DTR) bone marrow. CD11c-DTR mice are a well-described transgenic strain that facilitate depletion of certain subsets of CD11c + DCs following administration of DT (36) . For long-term depletion studies, bone marrow chimeras must be generated to prevent the fatalities observed following depletion of nonhematopoietic CD11c + cells. Two months following bone marrow reconstitution, the CD11c-DTR chimeric carriers were treated every third day with DT (2 ng/g) or PBS. This is the same dose of DT we used previously to deplete DCs in CD11c-DTR carrier mice (15) . After 3 wk of treatment, CD11c high DCs were reduced by 88% in the spleen, 88% the bone marrow, and 57% in the liver. Following depletion we then compared viral titers and CNS MHC I expression between the groups (Fig. 6, B-D) . No difference in serum (Fig. 6B) or CNS (Fig.   6C ) viral titers was observed in carrier mice that received DT. Compared with uninfected naive mice, elevated CNS MHC I was observed in all chimeric carrier mice; however, no decrease in CNS MHC I was observed in DT treated carrier mice when compared with PBS controls (Fig. 6D ). In concert, these data indicate that CD11c + DCs are a probable source of type 1 IFN in LCMV carrier mice, but the subsets depleted in CD11c-DTR mice do not have an impact on CNS MHC I or the viral set point.
Therapeutic clearance of LCMV from carrier mice reduces CNS MHC I expression
In our final line of experimentation, we addressed whether the elevated MHC I expression observed in carrier mice was dependent on persisting virus, or, alternatively, was developmentally imprinted from birth. If elevated MHC I was dependent on the persisting virus, we predicted that the expression pattern could be therapeutically corrected by purging LCMV from carrier mice. To purge LCMV, we performed immunocytotherapy (37) by adoptively transferring 2 × 10 7 memory splenocytes obtained from day 45 LCMV immune mice into carrier mice. It was shown that this treatment results in viral clearance from most peripheral tissues within 14 days and the CNS within 100 days (14) . Brains were harvested from carrier mice 124 days following adoptive immunotherapy (a time point following the CNS clearance phase) and compared with untreated carrier mice and uninfected controls for the level of MHC I expression ( Fig. 7 ). Viral clearance from the serum and CNS in all treated mice was confirmed by plaque assay (data not shown). Interestingly, a statistically significant reduction (p <0.021) in CNS MHC I expression was observed in treated when compared with untreated carrier mice. In fact, the levels were only slightly elevated above that observed in uninfected control mice and were not statistically different (p = 0.252).
These data indicate that persistent virus is responsible for the elevated MHC I expression observed in carrier mice.
gene expression. LCMV (24) and hepatitis B virus (38) are two excellent examples of viruses that minimally impact host gene expression patterns. Nevertheless, even the stealthiest pathogens are usually detected to some degree by the immune system, which can initiate a cascade of events that impact the host either negatively or positively. Analysis of carrier mice persistently infected from birth with LCMV provides an excellent model system to examine the influence that chronic innate immune stimulation has on host biology and function. Carrier mice on the C57BL/6 (B6) background are remarkably tolerant of LCMV persistence. These mice have a normal lifespan and show no signs of overt disease. However, when examined more closely, subtle defects were observed in B6 carrier mice such as deficiencies in memory formation (7, 24) and responses to other viral infections (22) . Interestingly, the deficiency in memory formation occurred despite a miniscule impact on host gene expression in the CNS (24) . When quantified using gene arrays, only 75 genes were found to be differentially regulated in the CNS of LCMV carrier mice and most of these genes fit with the molecular signature of a type I IFN response (24) , suggesting that innate immune sensors were continually tripped in carrier mice and that evolutionary pressures had not enabled or required LCMV to find a solution to this problem in its natural host.
Two previous studies found low, but detectable levels of type I IFN in the blood of LCMV carrier mice (10, 23) . Using this result and the CNS gene expression changes (24) as a foundation, we set out to address how the immunologically quiescent CNS compartment responded to chronic innate stimulation. Our studies revealed six important findings that directly link chronic innate immune stimulation by LCMV to elevated expression of Agpresenting machinery in the CNS. First, MHC I expression was increased significantly in the CNS and periphery (liver) of LCMV carrier mice, and the elevated protein observed on sagittal brain reconstructions mapped primarily to CNS vascular endothelium and microglia. Second, CNS MHC I expression decreased to baseline levels in carrier mice deficient in the IFN-αβ receptor, indicating that type I IFN was either directly or indirectly responsible for the elevated expression pattern. Third, when the source of the type I IFN was sought, increased IFN-β message was detected in the spleen, lymph nodes, and liver, but not the CNS, suggesting that the type I IFN was generated in peripheral tissues and distributed systemically by blood. Fourth, peripheral DCs represent one important source of type I IFN, but are not likely the only source in carrier mice. Fifth, chronic elevation of MHC I in the CNS of carrier mice did not require MyD88-dependent signaling, indicating that even if the MyD88-dependent Toll-like receptors are involved in the innate detection of LCMV (34), they are not an absolute requirement in this model system. Lastly, elevated MHC I expression was therapeutically corrected by purging LCMV with adoptive immunotherapy, demonstrating that the virus is indeed responsible for chronic innate immune stimulation and that the changes in CNS MHC I expression are reversible rather than permanent.
The pattern of MHC I expression observed in the CNS of carrier mice is quite interesting and fits with the type I IFN being peripherally rather than centrally derived. Previous studies have demonstrated that all cells within the CNS (oligodendrocytes, astrocytes, microglia, neurons, and endothelium) have the capacity to express MHC I, but neurons and astrocytes seem the most reluctant to do so (39) . In fact, some have postulated that the neurons might not express MHC I (16, 17) ; however, recent neurological (27) and immunological studies (40) have called this supposition into question. The most notable and easily detected increase in MHC I expression was observed on CNS vascular endothelium in carrier mice. Moreover, when measured flow cytometrically, MHC I was also increased on resident microglia. Increased MHC I expression on CNS vascular endothelium is interesting because it was recently shown that endothelium may represent a gateway into the CNS that restrict the entry of CTL through the expression of peptide-MHC I complexes (28) . If this theory is correct and generalizable, it is conceivable that LCMV carrier mice would have enhanced CTL surveillance of the CNS if Ag gained access to the vascular endothelium. The outcome of this enhanced surveillance, positive or negative, would likely depend on the scenario that plays out (e.g., pathogen clearance vs autoimmune disease).
To identify the mechanism by which CNS MHC I was chronically up-regulated in LCMV carrier mice, we sought guidance from our previously published gene array data, which revealed the molecular signature of type I IFN signaling (24) . We therefore generated a colony of carrier mice deficient in the IFN-αβ receptor. Interestingly, despite the presence of the persistent virus, deficiency in the IFN-αβ receptor reduced CNS MHC I expression to the levels observed in uninfected control mice. Type I IFNs are known to modulate MHC I expression (31) , and our data demonstrate that type I IFNs either directly or indirectly increase MHC I expression in carrier mice. Type I IFNs also contribute to the viral set point in LCMV carrier mice, possibly through the chronic induction of an antiviral state (41) . LCMV carrier mice have a well documented viral set point and consistently maintain 3-4 logs of virus in circulation with little deviation over time. Even irradiation or cyclophosphamide treatment of carrier mice has no impact on circulating viral titers (32) . One factor thought to contribute to the set point is down-regulation of viral glycoprotein expression by LCMV, which likely represents a self-limiting control mechanism that facilitates persistence by reducing viral replication (42) . However, our data show that the host also contributes to the viral set point through the chronic production of type I IFNs.
Many cells have the capacity to produce type I IFNs and an extremely diverse collection of cells are chronically infected by LCMV in carrier mice (13) . We therefore began our search for the source of type I IFN in carrier mice by examining expression at the transcription level. We selected a representative and commonly expressed type I IFN (i.e., IFN-β) and examined the degree to which it was expressed in mRNA extracted from the spleen, lymph nodes, liver, and CNS. Interestingly, elevated IFN-β was found in all peripheral tissues examined, but not the CNS. This result is supported by our previously published gene array data, which demonstrated the molecular signature of type I IFN signaling in the CNS of carrier mice, but no evidence of any type I IFN expression, either α or β (24) . Based on these findings, we postulate that the type I IFN in carrier mice is peripherally derived and then systemically distributed via the blood. Indeed, low levels of circulating type I IFN have been detected in blood obtained from carrier mice (10, 23) . We further postulated that the pattern of IFN-β expression could result from production by a LCMV infected cell population that is abundant in peripheral tissues, but not the CNS. One possibility we considered was DCs. Previous studies have shown that DCs can produce type I IFN upon being infected by LCMV (35) , and all conventional DC subsets from carrier mice harbor LCMV Ag (22) . When DCs were purified from carrier mice and examined, elevated IFN-β expression was observed. However, depletion of DCs from CD11c-DTR carrier mice had no impact on CNS MHC I expression, suggesting that the subset of CD11c high DCs depleted are not the only cells responsible for type I IFN production. It is known that DCs expressing low to intermediate levels of CD11c are not depleted in CD11c-DTR mice treated with DT (36) , and, therefore, it is possible that these remaining DCs, or an entirely different population altogether, continue to produce type I IFN.
The molecular mechanism(s) that give rise to chronic type I IFN production in LCMV carrier mice is of great interest and studies are underway to identify the innate sensor(s) involved in LCMV detection. Our initial studies indicate that the Toll-like receptors dependent on the MyD88 adaptor molecule are not required for the elevated MHC I or the viral set point in LCMV carrier mice, which were both linked in part to type I IFN signaling. We did note a decrease in the expected Mendelian frequency of MyD88 deficient carrier mice, suggesting that a developmental problem arose in utero in persistently infected mice deficient in MyD88. It was reported previously that immune responses to LCMV are impaired in the absence of MyD88 and TLR 2 (34); however, our results in carrier mice suggest that another non-Toll innate recognition system (e.g., RIG-I) (33) can detect LCMV and give rise to chronic type I IFN production.
Because persistent viral infections can have a negative impact on their host by inducing chronic immune stimulation, it is important to provide therapeutic relief when the infectious agent can be identified. In the LCMV system, we evaluated the reversibility of chronic immune stimulation by treating mice with virus-specific memory cells, an approach referred to as adoptive immunotherapy (37) . Importantly, this therapy purged mice of their persistent viral infection and reset CNS MHC I expression to near baseline levels. The slight elevation in MHC I observed in treated carrier mice when compared with uninfected controls could be explained by residual virus that remains in difficult-to-purge tissues (e.g., kidneys). It was reported previously that the kidneys of mice treated with adoptive immunotherapy remain infected for more than 200 days and even at that time clearance was often not complete (43) . Nevertheless, our data indicate that elevated CNS MHC I expression in carrier mice is not set during development, but rather is continually maintained by active viral persistence. In contrast, previous studies have shown that the memory deficits observed in carrier mice cannot be repaired following adoptive immunotherapy, indicating that some perturbations are locked into place (44) .
In conclusion, our studies demonstrate that LCMV cannot avoid detection by the innate immune system even after equilibrating with its murine host. This results in chronic and systemic production of type I IFNs, which elevates Ag presenting machinery both in the CNS as well as peripheral tissues (e.g., liver) (22) . Mice on a B6 background maintained in a pathogen-free environment are tolerant of chronic immune stimulation and do not present with overt disease. However, we theorize that chronic stimulation and systemic upregulation of Ag-presenting machinery cannot be tolerated on all genetic backgrounds and overt disease can result if proper regulatory mechanisms are not in place. For example, New Zealand white mice alone do not develop autoimmune lupus unless they are persistently infected from birth with LCMV (22) . In contrast, it is possible for a host to benefit from chronic immune stimulation, which is exemplified by the enhanced immunity observed in mice persistently infected gamma herpesvirus 68 or cytomegalovirus (9) . Our prediction is that the outcome of a persistent infection, in terms of impact on the host, is dictated by the tolerance of the genetic background and the nature of subsequent secondary infections. A dangerous balance exists when a persistent pathogen systemically trips innate sensors and continually keeps the immune system in a heightened state of awareness.
FIGURE 1.
Elevation of CNS MHC I in LCMV carrier mice. Sagittal brain reconstructions (n = 4 mice per group) stained with an anti-MHC I Ab (green) were compared between uninfected (A) and LCMV carrier mice (B) at 2-3 mo of age. Cell nuclei are shown in blue for anatomical purposes. Note the increased MHC I expression on the representative sagittal brain section from a LCMV carrier mouse. Quantitative image analysis revealed a statistically significant (p < 0.042) 4.1-fold increase in CNS MHC I expression in the brains of LCMV carrier mice (C). Bar graph data are represented as the mean ± SD. quantified, a statistically significant (p = 0.010) 3.0-fold increase in endothelial MHC I expression was observed in LCMV carrier mice (n = 4) compared with uninfected controls (n = 4) (I). The intensity difference is also evident on the two-color overlays used for quantification (green = CD31; red = MHC I) from carrier mice (H) vs uninfected controls (G). MHC I expression on endothelium appears in yellow. All bar graph data are represented as the mean ± SD. IFN-β mRNA expression in tissues from LCMV carrier mice. Semiquantitative nested RT-PCR was performed on mRNA extracted from naive and LCMV carrier tissues to determine potential sources of IFN-β. As positive control for the assay, mRNA was isolated from the spleens of adult mice 2 days following i.v. inoculation with 2 × 10 6 PFU LCMV clone 13, a strain of LCMV known to induce a sizeable IFN-β response (lanes 7 and 8). Note that elevated IFN-β expression was observed in the spleen, lymph nodes, and liver, but not the CNS of LCMV carrier mice (lanes 4, 5, and 6) when compared with uninfected controls (lanes 1, 2, and 3) . A β-actin RT-PCR was performed to ensure equal sample loading, and a DNA ladder is shown in lane 9. 
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Author Manuscript the IFN-αβ receptor also resulted in a significant (p < 0.05) 5.3-fold increase in serum viral titers as measured by plaque assay (E). All bar graph data are represented as the mean ± SD. 
Author Manuscript Deficiency in MyD88 expression does not influence CNS MHCI or viral titers in LCMV carrier mice. After intercrossing MyD88 +/− carrier mice, a statistically significant reduction (p = 0.008) in the expected Mendelian frequency of MyD88 −/− mice was observed (A; n = 50 offspring were examined). Deficiency in MyD88 did not alter viral titers (CNS or serum) as determined by plaque assay (B) or the level of CNS MHC I expression as determined by quantitative image analysis of sagittal brain reconstructions (C). Bar graph data in panels B and C are represented as the mean ± SD (n = 4-5 mice per group). 
